REG - N4 Pharma PLC - Grant of Options

N4 PharmaAnnouncement

28/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241128:nRSb9339Na&default-theme=true

RNS Number : 9339N  N4 Pharma PLC  28 November 2024

 

28 November 2024

 

N4 Pharma plc

("N4 Pharma" or the "Company")

 

Grant of Options

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments, gene therapy and
vaccines, announces that, on 27 November 2024, the Board granted 15 million
options (the "Options") over ordinary shares of 0.4p each in the Company to
certain directors of N4 Pharma as follows:

 

 Director                                         Number of options granted

 Nigel Theobold (Chief Executive Officer)         6,000,000
 Michael Palfreyman (Non-Executive Director)      3,000,000
 Dr Chris Britten (Non-Executive Chairman)        3,000,000
 Luke Cairns (Executive Director)                 3,000,000

 

The Options have an exercise price of 0.75p and vest in three equal tranches
on the first, second and third anniversaries from the date of grant.  The
Options have a term of ten years from the date of grant.

 

 

The FCA notifications, made in accordance with the requirements of the Market
Abuse Regulation, are appended below.

 

For more information please contact:

 

 N4 Pharma plc

 Nigel Theobald, CEO                                          Via N4 Pharma Investor Hub

 Luke Cairns, Executive Director

 Engage with us directly at N4 Pharma Investor Hub            Sign up at investors.n4pharma.com (https://investors.n4pharma.com/)

 SP Angel Corporate Finance LLP                               Tel: +44(0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Caroline Rowe (Corporate Finance)

 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
 Turner Pope Investments (TPI) Limited                        Tel: +44(0)20 3657 0050

 Joint Broker

 Andy Thacker

 James Pope

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for oncology, gene therapy and vaccines using its unique silica
nanoparticle delivery system called Nuvec® and Liptide, a unique
peptide/lipid delivery system via its subsidiary Nanogenics.

 

N4 Pharma's business model is to partner with companies developing products in
these fields to use Nuvec® or Liptide® as the delivery vehicle for these
products. As these products progress through pre‐clinical and clinical
programs, N4 Pharma will seek to receive upfront payments, milestone payments
and ultimately royalty payments once products reach the market.

 

For further information on the Company visit www.n4pharma.com
(http://www.n4pharma.com) or sign up at investors.n4pharma.com
(https://investors.n4pharma.com/) .

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them.

 

 1    Details of the person discharging managerial responsibilities / person closely
      associated
 a)   Name                                                         Nigel Theobold

 2    Reason for the notification
 a)   Position/status                                              Chief Executive Officer
 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         N4 Pharma plc
 b)   LEI                                                          213800I841D2RKMFK955
 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Options over Ordinary Shares of 0.4p each

      Identification code

                                                                   Identification code (ISIN) for N4 Pharma plc ordinary shares: GB00BYW8QM32

 b)   Nature of the transaction                                    Issue of options over ordinary shares of 0.4p each

 c)   Price(s) and volume(s)                                        Price(s)             Volume(s)
                                                                   0.75p exercise price  6,000,000

 
 d)   Aggregated information

      - Aggregated volume                                          n/a

      - Price
 e)   Date of the transaction                                      27 November 2024
 f)   Place of the transaction                                     Outside a trading venue

 

d)

Aggregated information

- Aggregated volume

- Price

 

n/a

e)

Date of the transaction

27 November 2024

f)

Place of the transaction

Outside a trading venue

 

 1    Details of the person discharging managerial responsibilities / person closely
      associated
 a)   Name                                                         Michael Palfreyman

 2    Reason for the notification
 a)   Position/status                                              Non-Executive Director
 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         N4 Pharma plc
 b)   LEI                                                          213800I841D2RKMFK955
 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Options over Ordinary Shares of 0.4p each

      Identification code

                                                                   Identification code (ISIN) for N4 Pharma plc ordinary shares: GB00BYW8QM32

 b)   Nature of the transaction                                    Issue of options over ordinary shares of 0.4p each

 c)   Price(s) and volume(s)                                        Price(s)             Volume(s)
                                                                   0.75p exercise price  3,000,000

 
 d)   Aggregated information

      - Aggregated volume                                          n/a

      - Price
 e)   Date of the transaction                                      27 November 2024
 f)   Place of the transaction                                     Outside a trading venue

 

d)

Aggregated information

- Aggregated volume

- Price

 

n/a

e)

Date of the transaction

27 November 2024

f)

Place of the transaction

Outside a trading venue

 

 

 1    Details of the person discharging managerial responsibilities / person closely
      associated
 a)   Name                                                         Dr Chris Britten

 2    Reason for the notification
 a)   Position/status                                              Non-Executive Chairman
 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         N4 Pharma plc
 b)   LEI                                                          213800I841D2RKMFK955
 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Options over Ordinary Shares of 0.4p each

      Identification code

                                                                   Identification code (ISIN) for N4 Pharma plc ordinary shares: GB00BYW8QM32

 b)   Nature of the transaction                                    Issue of options over ordinary shares of 0.4p each

 c)   Price(s) and volume(s)                                        Price(s)             Volume(s)
                                                                   0.75p exercise price  3,000,000

 
 d)   Aggregated information

      - Aggregated volume                                          n/a

      - Price
 e)   Date of the transaction                                      27 November 2024
 f)   Place of the transaction                                     Outside a trading venue

 

d)

Aggregated information

- Aggregated volume

- Price

 

n/a

e)

Date of the transaction

27 November 2024

f)

Place of the transaction

Outside a trading venue

 

 1    Details of the person discharging managerial responsibilities / person closely
      associated
 a)   Name                                                         Luke Cairns

 2    Reason for the notification
 a)   Position/status                                              Executive Director
 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         N4 Pharma plc
 b)   LEI                                                          213800I841D2RKMFK955
 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Options over Ordinary Shares of 0.4p each

      Identification code

                                                                   Identification code (ISIN) for N4 Pharma plc ordinary shares: GB00BYW8QM32

 b)   Nature of the transaction                                    Issue of options over ordinary shares of 0.4p each

 c)   Price(s) and volume(s)                                        Price(s)             Volume(s)
                                                                   0.75p exercise price  3,000,000

 
 d)   Aggregated information

      - Aggregated volume                                          n/a

      - Price
 e)   Date of the transaction                                      27 November 2024
 f)   Place of the transaction                                     Outside a trading venue

 

d)

Aggregated information

- Aggregated volume

- Price

 

n/a

e)

Date of the transaction

27 November 2024

f)

Place of the transaction

Outside a trading venue

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHEAEFXAEDLFAA